



GAU 1644

CASE 4-31157A/USN

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Peter Herridge  
Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
DIGAN ET AL.

ART UNIT: 1644

EXAMINER: EWOLDT, G.

APPLICATION NO: 09/480,236

FILED: JANUARY 10, 2000

FOR: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES  
THEREFORE

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

APR 17 2001

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

EP 0 669 316 B1 is substantially equivalent to U.S. Patent 5,637,613. Copies of both patents are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6763

  
Peter Herridge, M.D.  
Attorney for Applicants  
Reg. No. 42,658

Date: *April 10, 2001*



CASE 4-31157A/USN

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Peter Herridge  
Type or print name

*Peter Herridge*  
Signature

April 19 2007  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1644

DIGAN ET AL.

EXAMINER: EWOLDT, G.

APPLICATION NO: 09/480,236

FILED: JANUARY 10, 2000

FOR: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES  
THEREFOR

Assistant Commissioner for Patents  
Washington, D.C. 20231

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

*Peter Herridge*  
Peter Herridge, M.D.  
Attorney for Applicant  
Reg. No. 42,658

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6763  
Date:

April 10, 2007

04/16/2001 HGBREH1 00000011 190134 09480236  
01 FC:126 180.00 CH